Malaria Clinical Trial
Official title:
A Pilot Study of the Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities
Malaria accounts for over 40% of outpatient morbidity in Sierra Leone. These health risks have been heightened further by the recent civil war, persistent poverty, lack of access to affordable health care, and an increasing resistance of P.falciparum parasites to the most commonly used therapy Chloroquine, which now has a confirmed failure rate of 39%. This study will recruit 780 people from the Kroo-Bay community in Freetown. Healthy subjects would be randomised into two subgroups and given either homeopathic pellets or placebo tablets at four month intervals. They are then monitored repeatedly during the study period to assess the efficacy of the therapy in reducing the disease burden.
The main objective of this project is to evaluate the efficacy, costs and benefits of
homeopathic treatment therapies.This study will be conducted in the Kroo Bay community
within Freetown, the capital city of Sierra Leone. This is a region where malaria is endemic
with an annual average of one malaria episode per person.Further, given the high rates of
poverty, most residents cannot afford to purchase the conventional drugs used to treat the
malaria. Chloroquine, which is the cheapest drug available, is no longer efficacious for
P.falciparum parasites.
The study will utilize a longitudinal approach that is divided into three major phases. The
first is a pre-test period involving the preparation and review of protocols, staff
training, purchase of equipment and medical supplies. Phase two constitutes an open
randomised controlled trial phase that is divided into five stages. The first stage IIA
involves subject recruitment from the Kroo-Bay community in the capital city of Freetown.
Approximately 780 permanent residents (ages 18+) living within a radius of 10 km within the
community would be recruited. A questionnaire would be administered to evaluate personal
case histories, use of mosquito bed nets, frequency of malaria diagnoses, the kinds of
treatments used in the past, and knowledge of alternative treatment therapies. Other
variables such as age, height, weight, gender, occupation and socio-economic attributes
would be collected. All subjects would be tested for malaria using blood smears. Those who
test positive for malaria, with clinical symptoms such as high temperature (>37.5 C) and
high levels of parasitemia (asexual forms of P falciparum >5000ul blood) would be sent to
the local clinic for treatment. These individuals would constitute the first subgroup in the
study sample. The remaining subjects eligible for the clinical trial would be those with no
major underlying illnesses, normal body temperatures and a reduced load of asexual forms of
P falciparum < 5000ul blood). All subjects would be monitored for four months and asked to
return for their second prophylactic treatment in four months (Day 112).
The next stage (IIB) begins after four months during which subjects are retested for malaria
and based on their blood sample results (negative), healthy subjects would be given another
dose of the pellets. They will be monitored for another four months. The same protocol is
followed in the next three consecutive stages (IIC, IID, and IIE). During each follow-up
visit, the subjects are retested and those with negative results are placed on their regimen
for four months.
The clinical trial phase ends after stage IIE. In the third phase, a post-intervention
survey will be given to all subjects to evaluate the levels of awareness of malaria and
knowledge of alternative treatment remedies. All data measures including, residential
location, blood test results, health histories and socio-demographic attributes would be
compiled and analyzed statistically to evaluate the effectiveness of the homeopathic
treatment. The results are expected to be published in a scientific peer-reviewed journal.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |